Nazanin Khakpour

Nazanin Khakpour

Auto-generated profile, based on publicly available information

Nazanin Khakpour

Comprehensive Breast Program, Moffitt Cancer Center, Tampa, FL 33612, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
KEKelly M. Elleson
Kelly M. Elleson
KEKatherine Englander
Katherine Englander
JGJulia Gallagher
Julia Gallagher
NCNeha Chintapally
Neha Chintapally
WSWeihong Sun
Weihong Sun
MLMarie Catherine Lee
Marie Catherine Lee
Background: Axillary node status is an important prognostic factor in breast cancer. The primary aim was to evaluate tumor size and other characteristics relative to axillary disease. Materials and Methods: Single institution retrospective chart review of stage I-III breast cancer patients collected demographic and clinical/pathologic data from 1998–2019. Student’s t-test, Chi-squared test (or Fisher exact test if applicable), and logistic regression models were used for testing the association of pN+ to predictive variables. Results: Of 728 patients (mean age 59 yrs) with mean follow up of 50 months, 86% were estrogen receptor +, 10% Her2+, 78% ER+HER2−negative, and 10% triple-negative. In total, 351/728 (48.2%) were pN+ and mean tumor size was larger in pN+ cases compared to pN− cases (mean = 27.7 mm versus 15.5 mm) (p < 0.001). By univariate analysis, pN+ was associated with lymphovascular invasion (LVI), higher grade, Her2, and histology (p < 0.005). Tumor-to-nipple distance was shorter in pN+ compared to pN− (45 mm v. 62 mm; p< 0.001). Age < 60, LVI, recurrence, mastectomy, larger tumor size, and shorter tumor-nipple distance were associated with 3+ positive nodes (p < 0.05). Conclusions: Larger tumor size and shorter tumor-nipple distance were associated with higher lymph node positivity. Age less than 60, LVI, recurrence, mastectomy, larger tumor size, and shorter tumor-nipple distance were all associated with 3+ positive lymph nodes.

14 May 2011 in The Oncologist
Verified
Journal Article
Open access
PDF file
KTKiran K. Turaga
Kiran K. Turaga
ACAlec Chau
Alec Chau
JEJennifer Eatrides
Jennifer Eatrides
JKJohn Kiluk
John Kiluk
NKNazanin Khakpour
Nazanin Khakpour
MLMarie Catherine Lee
Marie Catherine Lee
Learning Objectives: After completing this course, the reader will be able to: Identify patients likely to benefit from preoperative axillary ultrasound.Define the clinical implications of a preoperative axillary ultrasound and FNA in patient care. CME This article is available for continuing medical education credit at CME.TheOncologist.com Purpose.: Preoperative axillary sonography with fine needle aspiration (FNA) in patients with invasive breast cancer identifies patients with nodal metastasis who can be spared further surgery. Indiscriminate use of the diagnostic modality can increase costs and yield inaccurate results. We evaluate the costs associated with the use of highly sensitive axillary ultrasonography in patients with stage ≥T2 tumors. Patients and Methods.: We constructed a decision analysis tree using TreeAge Pro 2009 software comparing direct hospital charges between patients with and without routine use of axillary ultrasound. Base case estimates were derived from our institutional data and compared with those derived from the literature. One- and two-way sensitivity analyses were performed to check the validity of our inferences. Results.: We found that, for the base case estimate with 35% lymph node positivity in stage ≥T2 tumors and sensitivity of the axillary ultrasound set at 86% with a specificity of 40%, the strategy to perform preoperative axillary ultrasound yielded rollback costs of $15,215, compared with $15,940 for surgery plus sentinel lymph node biopsy (cost difference, $725 per patient favoring axillary ultrasound). On two-way sensitivity analysis, the cost benefit for axillary ultrasound was not seen in patients with a low risk for nodal metastasis. Conclusion.: The adoption of routine preoperative axillary sonography with FNA is a lower-cost strategy than conventional strategies in patients with stage ≥T2 invasive breast cancer.

3 February 2010 in Cases Journal
Verified
Journal Article
Open access
PDF file
NRNicole D Riddle
Nicole D Riddle
HYHideko Yamauchi
Hideko Yamauchi
JCJamie Caracciolo
Jamie Caracciolo
DCDavid Cheong
David Cheong
NKNazanin Khakpour
Nazanin Khakpour
MBMarilyn Bui
Marilyn Bui
Giant cell tumor (GCT) is an aggressive, but usually benign bone neoplasm most commonly arising in the metaphysis/epiphyses of long bones. While they are categorized as benign tumors, they can be locally aggressive and clinically have metastatic potential. The most common locations of this tumor include the distal femur, proximal tibia, and distal radius. We report a GCT arising in an atypical location and mimicking a breast mass. This case was diagnosed at a large cancer center in Florida. Pertinent clinical findings were obtained from chart review and inter-departmental consultation. Radiologically, the initial impression included a deep-seated breast cancer with local chest wall invasion. Further evaluation revealed the mass to be an expansile rib lesion with extraosseous soft tissue invasion. Histological examination of the biopsy specimen showed bland multi-nucleated giant cells and mononuclear cells whose nuclei were morphologically similar. No necrosis, pleomorphism or mitotic activity was identified. No chondroid or osseous elements were present. The histological features of bland mononuclear and multinucleated giant cells along with the lack of any additional mesenchymal elements led to the diagnosis of giant cell tumor. Resection of tumor was performed. The patient is disease free as of the last follow-up visit. This case is important as it shows where the physician must keep this diagnosis in mind whenever a deeply located breast mast is present.

8 September 2019 in The Breast Journal
Verified
Journal Article
Closed access
PDF file
DPDavid T. Pointer
David T. Pointer
DDDiane M. Durgan
Diane M. Durgan
BKBela Kis
Bela Kis
NKNazanin Khakpour
Nazanin Khakpour
JKJohn V. Kiluk
John V. Kiluk

1 June 2016 in Annals of Plastic Surgery
Verified
Journal Article
Closed access
SPSangeetha Prabhakaran
Sangeetha Prabhakaran
MMMegan Melody
Megan Melody
RTRose Trotta
Rose Trotta
ALAmina Lleshi
Amina Lleshi
WSWeihong Sun
Weihong Sun
DDDeniz Dayicioglu
Deniz Dayicioglu
Women who have undergone prior augmentation mammoplasty represent a unique subset of breast cancer patients with several options available for breast reconstruction. We performed a single institution review of surgical outcomes of breast reconstruction performed in patients with breast cancer with prior history of subpectoral breast augmentation. Institutional review board-approved retrospective review was conducted among patients with previously mentioned criteria treated at our institution between 2000 and 2014. Reconstructions were grouped into 2 categories as follows: (1) removal of preexisting subpectoral implant during mastectomy with immediate tissue expander placement and (2) implant-sparing mastectomy followed by delayed exchange to a larger implant. We reviewed demographics, tumor features, and reconstruction outcomes of these groups. Fifty-three patients had preexisting subpectoral implants. Of the 63 breast reconstructions performed, 18 (28.6%) had immediate tissue expander placed and 45 (71.4%) had implant-sparing mastectomy followed by delayed implant exchange. The groups were comparable based on age, body mass index, cancer type, tumor grade, TNM stage at presentation, and hormonal receptor status. No significant difference was noted between tumor margins or subsequent recurrence, mastectomy specimen weight, removed implant volume, volume of implant placed during reconstruction, or time from mastectomy to final implant placement. Rates of complications were significantly higher in the tissue expander group compared to the implant-sparing mastectomy group 7 (38.9%) versus 4 (8.9%) (P = 0.005). Implant-sparing mastectomy with delayed implant exchange in patients with preexisting subpectoral implants is safe and has fewer complications compared to tissue expander placement. There was no difference noted in the final volume of implant placed, time interval for final implant placement, or tumor margins.

24 October 2017 in The Breast Journal
Verified
Journal Article
Closed access
PDF file
AKAnne Kuritzky
Anne Kuritzky
LWLauren Walheim
Lauren Walheim
NKNazanin Khakpour
Nazanin Khakpour